Statistically significant linear increase in use of antidepressants during the observed time period. by Jelena Filimonovic (22305307)

Statistically significant linear increase in use of antidementia medications and antipsychotics during the observed time period. by Jelena Filimonovic (22305307)

Join-point regression analysis of the statistically significant linear increase in use of antidepressants during the observed time period. by Jelena Filimonovic (22305307)

Increasing gaps and decreasing returns attenuate spending effects. by William Minozzi (8564712)

Join-point regression analysis of the statistically significant linear increase in use of antidementia and antipsychotics during the observed time period. by Jelena Filimonovic (22305307)

“…<p>Before COVID-19 pandemic among anti-dementia drugs, donepezil showed a steady increase starting from 2008, rivastigmine from 2010, while memantine exhibited a significant increase between 2006 and 2008, followed by a sharp rise thereafter from 2018. …”

Statistically significant linear increase in use of psychostimulants and nootropic drugs, anxiolytics, sedatives and hypnotics, gabapentinoids during the observed time period. by Jelena Filimonovic (22305307)

Statistically significant linear decrease in use of antidepressants, antipsychotics, psychostimulants and nootropic drugs, anxiolytics, sedatives and hypnotics during the observed time period. by Jelena Filimonovic (22305307)

Join-point regression analysis of the statistically significant linear increase in use of anxiolytics, psychostimulants and noot ropic drugs, sedatives and hypnotics, gabapentinoids during the observed time period. by Jelena Filimonovic (22305307)

Join-point regression analysis of the statistically significant linear decrease in use of antidepressants, antipsychotics, psychostimulants and nootropic drugs, anxiolytics, sedatives and hypnotics during the observed time period. by Jelena Filimonovic (22305307)

“…<p>A significant decline for fluphenazine was observed from 2014 to 2017, followed by a sharp increase starting from 2017.…”

Phase 2 significant effects. by Wendy C. Crone (2262169)

Phase 1 significant effects. by Wendy C. Crone (2262169)

Larger example of stimuli with cue relevant for Task 3. by Marcel F. Hinss (14675457)

Subjects:

Cohesion characteristics and statistical significance analysis of different ingredients across IDDSI levels^b'*'. by Muxi Chen (9294270)

Subjects:

Adhesion characteristics and statistical significance analysis of different ingredients across IDDSI levels^b'*'. by Muxi Chen (9294270)

Subjects:

Hardness characteristics and statistical significance analysis of different ingredients across IDDSI levels^b'*'. by Muxi Chen (9294270)

Subjects:

Multiple linear regression analysis results. by Muxi Chen (9294270)

Subjects:

Distribution of the same ingredient across different IDDSI levels (Percentages and frequencies) and statistical significance analysis (Chi-square analysis). by Muxi Chen (9294270)

Subjects:

MS decreases the larger amplitude distribution in adult rats. by Jesús David Ayala-Rodríguez (17364296)

Scatterplot of observed barrier scores against knowledge scores (top) and confidence scores (bottom) with linear line of best fit. by Lisa Thiele (6468056)

Distribution of different ingredients at the same IDDSI level (Percentage and frequency) and statistical significance analysis (Chi-square test)^b'*'. by Muxi Chen (9294270)

Subjects: